Abstract
Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have